Lundbeck
HLUN-B.CO
₹502.70
Share price
3.84%
Change (1 day)
12.49%
Change (1 year)
Categories
Lundbeck is a Danish pharmaceutical company that produces various pharmaceutical products and has the indications schizophrenia, depression, Parkinson's disease and sleep disorders.
Revenue for Lundbeck (HLUN-B.CO)
Revenue in 2024 (TTM): ₹267.33 Billion
According to Lundbeck's latest financial reports the company's current revenue (TTM 
) is ₹272.32 Billion. an increase over the revenue in the year 2023 that were of ₹241.25 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Lundbeck from 2009 to 2024
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2024 | ₹272.84 B | 13.09% |
| 2023 | ₹241.25 B | 12.91% |
| 2022 | ₹213.67 B | 12.56% |
| 2021 | ₹189.83 B | -5.38% |
| 2020 | ₹200.62 B | 8.2% |
| 2019 | ₹185.41 B | -6.02% |
| 2018 | ₹197.28 B | 16.07% |
| 2017 | ₹169.96 B | 7.88% |
| 2016 | ₹157.55 B | 9.61% |
| 2015 | ₹143.74 B | -4.12% |
| 2014 | ₹149.91 B | -10.5% |
| 2013 | ₹167.50 B | 18.22% |
| 2012 | ₹141.69 B | -9.7% |
| 2011 | ₹156.92 B | 34.23% |
| 2010 | ₹116.90 B | -3.07% |
| 2009 | ₹120.60 B |